15-min delayed · Jul 28, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 3 firms covering ProQR Therapeutics BV, 3 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. The target range is very wide, $3.00 to $10.00 (about 3.3x), which points to deep disagreement over how to value the company rather than near-term timing. The average target of $6.33 sits 260% above the current $1.76. The rating mix has stayed broadly stable, with Buy-side ratings easing from 4 to 3 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.14 next quarter toward $-0.68 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS3 ratings
Moderate Buy
Strong Buy00%
Buy3100%
Hold00%
Sell00%
Strong Sell00%
Based on 3 analysts giving stock ratings to ProQR Therapeutics BV.
As of Jul, 3 of 3 firms rate PRQR a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
PRQR EPS & revenue forecast
EPS · NEXT QUARTER
$-0.14
Range $-0.14 – $-0.14 · 1 analysts · +13% YoY
Next period, 1 analysts expect ProQR Therapeutics BV to earn $-0.14 a share (range $-0.14 – $-0.14), versus $-0.12 a year earlier. Full-year consensus is $-0.60, growing to $-0.68 the year after.
REVENUE · NEXT QUARTER
$5.2M
Range $3.8M – $6.0M · 1 analysts · +56% YoY
Revenue is expected to reach $5.2M (range $3.8M – $6.0M), +55.5% year-over-year. Full-year consensus is $15.3M, rising to $16.2M next year.
Top analysts covering ProQR Therapeutics BV
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on PRQR.
#1
Andrew Fein
HC Wainwright & Co. · Rank #35
Buy
$12.00+581.8% to target
Overall win rate
46%
+ Follow
#2
Jonathan Wolleben
JMP Securities · Rank #38
Buy
$8.00+354.5% to target
Overall win rate
44%
+ Follow
#3
Keay Nakae
Chardan Capital · Rank #130
Buy
$3.00+70.5% to target
Overall win rate
41%
+ Follow
#4
GC
Gavin Clark-Gartner
Evercore ISI Group
Buy
$6.00+240.9% to target
Coverage
—
+ Follow
#5
Catherine Novack
Jones Trading
Buy
$10.00+468.2% to target
Coverage
—
+ Follow
PRQR stock forecast FAQ
What is PRQR's average 12-month price target?+
The 3 analysts with a live target average $6.33 for ProQR Therapeutics BV over the next 12 months, ranging from a $10.00 high to a $3.00 low.
Is PRQR stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 3 analyst ratings, 3 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for PRQR?+
The Street-high target is $10.00 (Jones Trading), and the Street-low is $3.00 (Chardan Capital). The average of all 3 active targets is $6.33.
How many Wall Street analysts cover PRQR?+
3 analysts have an active rating on ProQR Therapeutics BV, and 3 firms carry a live 12-month price target.
Who is the most accurate analyst covering PRQR?+
Among analysts who currently cover PRQR, Andrew Fein of HC Wainwright & Co. has the strongest overall Quantellect track record (Rank #35). Their current call is Buy with a $12.00 target.
What is ProQR Therapeutics BV's projected EPS for next quarter?+
The consensus estimate is $-0.14 per share (range $-0.14 – $-0.14) across 1 analysts. Full-year EPS is projected at $-0.60, rising to $-0.68 the following year.
How much revenue is ProQR Therapeutics BV expected to report next quarter?+
Consensus revenue is $5.2M (range $3.8M – $6.0M). Full-year revenue is projected at $15.3M, growing to $16.2M next year.
Have analysts been upgrading or downgrading PRQR lately?+
As of Jul, 3 of 3 firms rate PRQR a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their PRQR calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
